Intervention not reported
Health‐related quality of life · people with non‐rhabdomyosarcoma soft tissue sarcoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival (reported as mortality) · high‐risk neuroblastoma patients treated with autologous HSCT
Retinoic acid postconsolidation therapy showed no clear difference in overall survival (reported as mortality) compared with no further treatment (low certainty).
1 finding from 1 review
Treatment‐related mortality ‐ not reported · high‐risk neuroblastoma patients treated with autologous HSCT
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Progression‐free survival ‐ not reported · high‐risk neuroblastoma patients treated with autologous HSCT
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Event‐free survival · high‐risk neuroblastoma patients treated with autologous HSCT
Retinoic acid postconsolidation therapy showed no clear difference in event‐free survival (reported as relapse, disease progression, death… compared with no further treatment (low certainty).
1 finding from 1 review
Early toxicity ‐ not reported · high‐risk neuroblastoma patients treated with autologous HSCT
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Late toxicity including secondary malignancies ‐ not reported · high‐risk neuroblastoma patients treated with autologous HSCT
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life ‐ not reported · high‐risk neuroblastoma patients treated with autologous HSCT
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality attributable to hepatic veno‐occlusive disease ( · People undergoing autologous or HLA identical allogeneic bone marrow transplant with a variety of malignant diseases or aplastic anaemia
Summary of findings: Heparin showed no clear difference in mortality attributable to hepatic veno‐occlusive disease ( compared with no treatment (low certainty).
1 finding from 1 review
Quality of life · People undergoing autologous or HLA identical allogeneic bone marrow transplant with a variety of malignant diseases or aplastic anaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Frequency of adverse events ( · People undergoing autologous or HLA identical allogeneic bone marrow transplant with a variety of malignant diseases or aplastic anaemia
It is very uncertain whether summary of findings: Heparin changes frequency of adverse events ( compared with no treatment (very low certainty).
1 finding from 1 review
Incidence of hepatic veno‐occlusive disease ( · People undergoing autologous or HLA identical allogeneic bone marrow transplant with a variety of malignant diseases or aplastic anaemia
It is very uncertain whether summary of findings: Heparin changes incidence of hepatic veno‐occlusive disease ( compared with no treatment (very low certainty).
1 finding from 1 review
Overall survival ( · People undergoing autologous or HLA identical allogeneic bone marrow transplant with a variety of malignant diseases or aplastic anaemia
It is very uncertain whether summary of findings: Heparin changes overall survival ( compared with no treatment (very low certainty).
1 finding from 1 review
All‐cause mortality at 100 days post‐transplant · People undergoing autologous or HLA identical allogeneic bone marrow transplant with a variety of malignant diseases or aplastic anaemia
Summary of findings: Heparin showed no clear difference in all‐cause mortality at 100 days post‐transplant ( compared with no treatment (low certainty).
1 finding from 1 review
Number of participants with at least 1 clinically significant bleeding event up to 30 days from study entry · People with a haematological disorder
Prophylactic platelet transfusion at threshold of 10,000 showed no clear difference in numbers of participants with at least 1 clinically significant… compared with higher transfusion threshold (20,000 or 30,000) (low certainty).
1 finding from 1 review
Number of participants with WHO grade 3 or 4 bleeding up to 30 days from study entry · People with a haematological disorder
Prophylactic platelet transfusion at threshold of 10,000 showed no clear difference in number of participants with WHO Grade 3 or 4 bleeding up to 30 days… compared with higher transfusion threshold (20,000 or 30,000) (low certainty).
1 finding from 1 review
Time to first bleeding episode (days) · People with a haematological disorder
Prophylactic platelet transfusion at threshold of 10,000 showed no clear difference in time to first bleeding episode (days) compared with higher transfusion threshold (20,000 or 30,000) (low certainty).
1 finding from 1 review
Mortality from all causes up to 30 days from study entry · People with a haematological disorder
Prophylactic platelet transfusion at threshold of 10,000 showed no clear difference in mortality from all causes up to 30 days from study entry compared with higher transfusion threshold (20,000 or 30,000) (low certainty).
1 finding from 1 review
Quality of life ‐ not reported · People with a haematological disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of participants with at least 1 clinically significant bleeding event up to 30 days from study entry · People with a haematological disorder
Prophylactic platelet transfusions with low‐dose schedule showed no clear difference in number of participants with at least 1 clinically significant… compared with prophylactic platelet transfusions with standard‐dose schedule (moderate certainty).
1 finding from 1 review